Switching to aripiprazole or ziprasidone could improve weight and other cardiometabolic outcomes in patients with serious mental illness, according to a systematic review and meta-analysis publishes online in Schizophrenia Bulletin.
A machine learning algorithm that previously predicted people with schizophrenia with 87% accuracy has now identified healthy first-degree relatives of such patients with the highest self-reported schizotypal personality scores.
Long-acting injectable (LAI) paliperidone palmitate significantly improved outcomes in patients with schizophrenia despite duration of illness, but those with shorter illness duration showed the best improvement, a study found.
A majority of inpatients with schizophrenia who were treated with electroconvulsive therapy (ECT) demonstrated clinical improvement, irrespective of whether they were capable of consenting before psychiatric treatment, a study found.
Two advisory committees appointed by the US Food and Drug Administration (FDA) have voted in favor of ALKS 3831, a combination of olanzapine and the novel molecular entity samidorphan, Alkermes announced.
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”